PepGen Inc.
PEPGHealthcare|Biotechnology|US
$2.47
+0.15 (+6.47%)
DCF Value
$1.01
Tangible Book / Share
$1.73
Cash / Share
$1.69
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06667453 A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 | Myotonic Dystrophy 1 | P2 | Recruiting | 24 | RCT, Double-blind | PGN-EDODM1 |
| NCT07220603 An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) | Myotonic Dystrophy 1 | P2 | Recruiting | 48 | Open-label | PGN-EDODM1 |
| NCT06079736 A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment | Duchenne Muscular Dystrophy | P2 | Terminated | 7 | Open-label | PGN-EDO51 |
| NCT06833931 A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment | Duchenne Muscular Dystrophy (DMD) | P2 | Withdrawn | — | RCT, Double-blind | IV infusion |
| NCT06204809 Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 | Myotonic Dystrophy 1 | P1 | Completed | 24 | RCT, Double-blind | PGN-EDODM1 for infusion |